Last reviewed · How we verify
Helicobacter pylori eradication
Helicobacter pylori eradication involves the use of antibiotic-based combination therapy to eliminate the bacterium from the gastric mucosa.
Helicobacter pylori eradication involves the use of antibiotic-based combination therapy to eliminate the bacterium from the gastric mucosa. Used for Helicobacter pylori infection eradication, Prevention of gastric cancer, Prevention of peptic ulcer disease.
At a glance
| Generic name | Helicobacter pylori eradication |
|---|---|
| Also known as | Chemoprevention |
| Sponsor | National Cancer Center, Korea |
| Drug class | Antibiotic combination therapy / Proton pump inhibitor-based regimen |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Oncology (cancer prevention) |
| Phase | FDA-approved |
Mechanism of action
H. pylori eradication typically employs triple or quadruple therapy combining proton pump inhibitors with antibiotics (such as amoxicillin, clarithromycin, or metronidazole) to suppress gastric acid and kill the bacteria. This approach aims to prevent peptic ulcer disease, gastric cancer, and other H. pylori-associated conditions. The National Cancer Center's marketed regimen represents a standardized eradication protocol.
Approved indications
- Helicobacter pylori infection eradication
- Prevention of gastric cancer
- Prevention of peptic ulcer disease
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Taste disturbance
- Headache
Key clinical trials
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (NA)
- Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication. (NA)
- H. Pylori Eradication With Argon Plasma During Endoscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Helicobacter pylori eradication CI brief — competitive landscape report
- Helicobacter pylori eradication updates RSS · CI watch RSS
- National Cancer Center, Korea portfolio CI